Blue Ash Therapeutics, LLC, founded in December in Cincinnati, Ohio, is a privately funded pharmaceutical services provider focused on developing cardiovascular drugs. The company's core mission is to bring innovative treatments for heart arrhythmias to market, with a vision of improving patient outcomes in cardiovascular health. Blue Ash Therapeutics offers services in pharmaceutical product development, clinical research, and business development. Their flagship product is azimilide dihydrochloride, a promising drug for treating heart arrhythmias.

Notable affiliated individuals include the Cincinnati-based clinical and regulatory development team that successfully reactivated the azimilide IND and secured FDA agreement through the Special Protocol Assessment (SPA) process. Key investors are private funders who have enabled the company's strategic acquisitions and development initiatives. Blue Ash Therapeutics' significant achievements include acquiring the global development license for azimilide from Warner Chilcott and advancing its clinical trials. The company has made a substantial impact by progressing towards bringing a critical cardiovascular treatment to market, potentially benefiting numerous patients with heart arrhythmias.